I’m a bit behind and therefore am not part of the slew of commentary that flowed from the Supreme Court’s decision in Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1248 (2023), addressing Amgen’s claims to “antibodies that (1) bind...more
In 2021, the Federal Circuit determined that Amgen’s biotech antibody patents lack enablement, i.e., the specification did not teach one of ordinary skill in the art how to make and use the invention without undue...more
Based on the denial of rehearing and the Amgen v. Sanofi decision itself, inventors should:
Claim as many separate species as possible.
Attempt to fashion genus claims that have a limited number of members supported...more
One of the most interesting and promising areas of medical research today involves the use of T-Cell therapies, which offer hope and promise as a new approach to cancer treatment. It has also made for a robust climate for...more
7/21/2020
/ Biotechnology ,
Damages ,
Intellectual Property Litigation ,
Jury Verdicts ,
Medical Research ,
Patent Infringement ,
Patent Litigation ,
Patent Royalties ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Written Descriptions